Clinical Update on Bexmarilimab – the First-in-Class Anti-CLEVER-1 mAb

Time: 9:30 am
day: Day One

Details:

• FiH Phase I/II study showing extended survival in last line patients
• Review biomarkers to identify responding patients
• Outline future development plans based on the FiH Phase I/II results

Speakers: